FINWIRES · TerminalLIVE
FINWIRES

$ENSG

11 stories mentioning ENSGUpdated 22d ago

Every FINWIRES story that references ENSG, newest first.

Wire

Ensign's 2026 Guidance Increase Reflects 'Strong' Operational, M&A Momentum, RBC Says

Ensign's (ENSG) higher adjusted earnings and revenue guidance reflects "strong" operational and M&A momentum, RBC Capital Markets analysts said in a Monday note.The company's new guidance appears achievable considering its track record of operational outperformance, along with momentum in same-store occupancy and acquisitions heading into the second half of the year, the analysts said.RBC increased Ensign's 2026 adjusted earnings estimate to $7.73 from $7.55, higher than a FactSet consensus estimate of $7.65."Following multiple short reports published intra-quarter, we are pleased to see management come forward with greater detail on ENSG's clinical quality," the analysts said.RBC retained an outperform rating on the stock and increased its price target to $228 from $222.Price: $180.30, Change: $+2.23, Percent Change: +1.25%

$ENSG
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.8%.The iShares Biotechnology ETF (IBB) advanced 0.7%.In corporate news, Forte Biosciences (FBRX) shares soared 39% after it agreed to be acquired by Argenx (ARGX) in a deal worth about $2.2 billion. Argenx shares were down 2.5%.AstraZeneca (AZN) shares were up 0.8% after it posted higher Q2 core earnings and revenue, and raised its interim dividend.Ensign (ENSG) shares climbed nearly 3% after it reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.Veru (VERU) said Monday it has completed enrollment in a phase 2 trial evaluating its experimental drug enobosam in combination with semaglutide, in about 200 adults aged 65 and older with obesity. Veru shares gained 3.1%.

$ARGX$AZN$ENSG$FBRX$VERU
Sectors

Sector Update: Healthcare Stocks Advance Monday Afternoon

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index rising 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.9%.The iShares Biotechnology ETF (IBB) advanced 0.5%.In corporate news, Forte Biosciences (FBRX) shares soared 39% after it agreed to be acquired by Argenx (ARGX) in a deal worth about $2.2 billion. Argenx shares were down 2.2%.AstraZeneca (AZN) shares were up marginally after it posted higher Q2 core earnings and revenue, and raised its interim dividend.Ensign (ENSG) shares climbed 4% after it reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.

$ARGX$AZN$ENSG$FBRX
Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Monday

Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) advancing by 0.5%.AstraZeneca (AZN) stock was up 0.8% after the company posted higher Q2 core earnings and revenue, and raised its interim dividend.Ensign Group (ENSG) shares were up nearly 11% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.Argenx (ARGX) has agreed to buy Forte Biosciences (FBRX) for $77 per share in cash. Shares of Forte Biosciences were up more than 39% pre-bell.

$ARGX$AZN$ENSG$FBRX$IBB$XLV
Wire

Ensign Group Remains Attractive on Strong Skilled-Nursing Trends, Oppenheimer Says

Ensign Group (ENSG) remains an attractive long-term investment as strong skilled-nursing occupancy, a favorable reimbursement and regulatory backdrop, and an active acquisition pipeline outweigh concerns about managed-care volumes, Oppenheimer said Wednesday in a report.The stock trades at about 11 times estimated 2027 earnings before interest, taxes, depreciation, amortization and rent, below its five-year average of 14 times and 10-year average of 12 times, Oppenheimer said. The discount offers a buying opportunity because operating trends remain solid despite recent market "noise," the report said.Same-store occupancy rose 190 basis points to a record 84.3% in Q1, while Ensign's 71 locations added since early 2025 and robust acquisition outlook provide further room for growth, the report said.Ensign's strong cash flow and balance sheet should also help it continue acquisitions and withstand economic uncertainty, the report said.Oppenheimer maintained its outperform rating on Ensign stock with a $210 price target.Price: $169.21, Change: $-1.66, Percent Change: -0.97%

$ENSG
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 2.3%.The iShares Biotechnology ETF (IBB) climbed 2.1%.In corporate news, AbbVie (ABBV) and other healthcare stocks were rising after the Trump administration reportedly proposed a new rule to curb hospital drug markups in Medicare. According to The Associated Press, the rule targets hospitals in the 340B program, which allows them to buy outpatient drugs at reduced prices for low-income patients but often bill insurers at higher rates and keep the difference. AbbVie rose 3.8%, Johnson & Johnson (JNJ) was up 3.2%, Bristol-Myers Squibb (BMY) climbed 3.4%, and Merck (MRK) added 2.7%.Crinetics Pharmaceuticals (CRNX) shares jumped 9% after UBS started coverage of the stock with a buy rating and a price target of $55 per share.Ensign (ENSG) shares rose 1.4% after the company said it has purchased the real estate and operations of two skilled nursing facilities in Texas.DarioHealth (DRIO) shares jumped 5.9% after it said Thursday that a health insurer in the US extended its agreement with the company and expanded the scope by adding its AI-powered hypertension offering.

$ABBV$BMY$CRNX$DRIO$ENSG$JNJ$MRK
Sectors

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.1%.The iShares Biotechnology ETF (IBB) advanced 1.6%.In corporate news, AbbVie (ABBV) and other healthcare stocks were rising after the Trump administration reportedly proposed a new rule to curb hospital drug markups in Medicare. According to The Associated Press, the rule targets hospitals in the 340B program, which allows them to buy outpatient drugs at reduced prices for low-income patients but often bill insurers at higher rates and keep the difference. AbbVie rose 3.2%, Johnson & Johnson (JNJ) was up 2.9%, Bristol-Myers Squibb (BMY) gained 2.4%, and Merck (MRK) added 2.2%.Ensign (ENSG) shares rose 1.7% after the company said it has purchased the real estate and operations of two skilled nursing facilities in Texas.Exelixis (EXEL) offers balanced risk-reward ahead of several key catalysts, with its Zanzalintinib therapy well positioned for success in a non-clear cell renal cell carcinoma, or nccRCC, trial readout in the second half of 2026 that could lift the stock, UBS Securities said. The firm raised its price target on Exelixis to $52 from $43 and reiterated its neutral rating. Exelixis shares added 1.8%.

$ABBV$BMY$ENSG$EXEL$JNJ$MRK
Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Thursday

Healthcare stocks were rising pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Ensign Group (ENSG) shares were up more than 2% after the company said it has purchased the real estate and operations of two skilled nursing facilities in Texas.Hutchmed (HCM) stock was up more than 6% after the company said China's National Medical Products Administration granted conditional approval to marketing application of its therapy, Orpathys, to treat certain patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.Takeda Pharmaceutical (TAK) has partnered with Insilico Medicine to use the latter's Pharma.AI platform to advance drug candidates across selected therapeutic areas, Hong Kong-listed Insilico said. Shares of Takeda Pharmaceutical were up more than 2% premarket.

$ENSG$HCM$IBB$TAK$XLV
Sectors

Sector Update: Healthcare

Health care stocks were rising pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.9%.Ensign Group (ENSG) shares were up more than 2% after the company said it has purchased the real estate and operations of two skilled nursing facilities in Texas.

$ENSG
Wire

Ensign Group's Regulatory, Reimbursement Concerns 'Overblown,' Oppenheimer Says

Ensign Group's (ENSG) recent stock price drop presents a buying opportunity, as regulatory and reimbursement concerns are "overblown," Oppenheimer said in a note Monday.With the company maintaining its strong operational performance, it should be able to handle volatility in managed care admissions and referrals, which represent about 14% of patient days and 20% of revenue, Oppenheimer analysts said.Ensign's occupancy percentage has risen to 84.3% but remains below its competitors'. The difference can be partially explained by market-related factors, and presents a long-term upside for the company, the analysts said.Oppenheimer also pointed to Ensign's acquisition pipeline as a driver of growth, noting that the company has added 71 locations since the start of 2025 and continues to see a healthy pipeline of merger and acquisition opportunities.Ensign's strategy of acquiring underperforming assets and unlocking operational upside from those facilities has helped it outperform in the historically challenging skilled nursing facility operating and reimbursement environment, according to the note.Oppenheimer maintained the company's stock rating at outperform, with a price target of $210.Price: $165.20, Change: $-2.46, Percent Change: -1.46%

$ENSG
Wire

Ensign Delivers 'Impressive' Start to 2026, RBC Says

Ensign Group (ENSG) delivered a beat-and-raise in Q1, with strong sequential managed care growth seen rebutting clinical review concerns, RBC Capital Markets said in a note Friday.The note said it was another "impressive" quarter, with EBITDA and EBITDAR both exceeding market expectations.The report also said investors have focused on managed care referral volume following UnitedHealth's comments on increased clinical scrutiny to limit Skilled Nursing Facility admissions."We are encouraged by ENSG's strong sequential managed care census growth, robust acquisition pipeline, and management's confident tone on payer diversification," the note said.The report also said the company continues to execute its mergers and acquisition strategy, with an accelerating pipeline into Q2 and Q3.RBC kept its outperform rating with a price target of $222.Price: $181.82, Change: $-1.90, Percent Change: -1.03%

$ENSG

Track with the FINWIRES app suite

FolioX
FolioX
Track ENSG in your portfolio
WheelAI
WheelAI
Analyze ENSG options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ENSG